New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 28, 2014
12:42 EDTDANOY, HSPHospira, Danone rise following report of deal talks
Hospira (HSP) and Danone (DANOY) are both climbing after The Financial Times reported that Hospira is in talks about acquiring Danone's medical nutrition business. Meanwhile, Wells Fargo estimated that the deal could be 20%-22% accretive to Hospira's EPS. WHAT'S NEW: French consumer products company Danone is in talks about selling its medical nutrition business to injectable drug maker Hospira, The Financial Times reported yesterday, citing multiple unnamed sources. In the wake of the deal, Hospira could move its tax base to Europe and potentially reduce its tax bill, the newspaper reported. ANALYST REACTION: In a note to investors today, Wells Fargo indicated that it "wouldn't be surprised" if Hospira made the deal. The transaction could raise Hospira's earnings per share by 9%-12% in 2015-2017, excluding operational synergies, if the transaction is carried out in all stock, the firm estimated. If the deal is done in 50% stock and 50% cash, Hospira's EPS could get a 20%-22% boost, excluding operational synergies, the firm estimated. Wells calculated that Hospira's tax bill would be cut to 21% in 2015 and 19% afterwards, from the firm's current forecast of tax rates ranging from 24%-26% from 2015-2017. However, Wells Fargo indicated that it did not see a clear strategic rationale for the deal from Hospira's perspective. It kept a Market Perform rating on the stock. PRICE ACTION: In early afternoon trading, Hospira rose 1.7% to $52.62 and Danone shares trading in New York added nearly 1% to $15.
News For HSP;DANOY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 27, 2015
16:15 EDTHSPHospira: No Form 483 observations issued after inspection of Costa Rica facility
Subscribe for More Information
February 26, 2015
09:41 EDTHSPHospira launches generic Remicade, WSJ says
Subscribe for More Information
February 20, 2015
06:25 EDTDANOYDanone board to ask shareholders to approve increased dividend of EUR1.50
Subscribe for More Information
06:24 EDTDANOYDanone targets 2015 organic growth in sales of between 4%-5%
Danone assumes that economic conditions will remain difficult and unstable overall, with fragile or even deflationary consumer trends in Europe, emerging markets undermined by volatile currencies, and difficulties specific to a few major markets, in particular the CIS. In 2015, Danone also anticipates marked but varied trends in the cost of major strategic raw materials, particularly milk; lower prices in Europe and the United States in the first half, with a rebound likely in the second half of the year, and gradual price increases in emerging countries all year long. Altogether, Danone anticipates a moderate rise in the cost of main raw materials and packaging in 2015. Sees slight growth in trading operating margin in 2015.
06:22 EDTDANOYDanone reports FY14 EPS EUR2.62
Subscribe for More Information
06:18 EDTDANOYDanone warns of volatility in years ahead, sees 'difficult' conditions in 2015
Subscribe for More Information
February 19, 2015
06:17 EDTHSPHospira Inflectra patient registry reports interim results in treatment of IBD
Data have been presented on the use of Hospira's Inflectra, the world's first approved biosimilar monoclonal antibody, or mAb, at the European Crohn's and Colitis Organisation Inflammatory Bowel Diseases, or ECCO-ibd, conference. Results show a comparable response in patients treated with Inflectra to that expected with the reference product, Remicade, for inducing and maintaining remission in Crohn's disease, or CD, and ulcerative colitis, or UC. These data add to the body of evidence supporting Inflectra's use in inflammatory bowel disease, or IBD. Results presented from the ongoing independent, prospective, nationwide study in Hungary show that for the first 90 patients, treated with Inflectra, reductions compared with baseline were seen in validated measures of disease activity after both two and six weeks of treatment. C-reactive protein, or CRP, a marker of inflammation, was also decreased during induction therapy for UC. Four of the 90 patients showed an allergic reaction to treatment, all of who had previously received anti-TNF medication. The abstract can be found at: P314 Biosimilar infliximab in inflammatory bowel diseases: first interim results from a prospective nationwide observational cohort.
February 18, 2015
10:05 EDTDANOYOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Agnico Eagle (AEM) upgraded to Overweight from Neutral at JPMorgan... Amarin (AMRN) upgraded to Buy from Neutral at SunTrust... Capital Product (CPLP) upgraded to Accumulate from Neutral at Global Hunter... Carlyle Group (CG) upgraded to Buy from Neutral at Citigroup... Danone (DANOY) upgraded to Neutral from Underperform at Exane BNP Paribas... Express (EXPR) upgraded on lower promotional activity at Piper Jaffray... Kforce (KFRC) upgraded to Outperform from Market Perform at Avondale... Legg Mason (LM) upgraded to Buy from Hold at Jefferies... Rackspace (RAX) upgraded following Q4 results at Pacific Crest... Rosetta Resources (ROSE) upgraded to Buy from Neutral at Global Hunter... SeaChange (SEAC) upgraded to Buy from Hold at Noble Financial... Valero (VLO) upgraded to Outperform from Neutral at Credit Suisse... Veeco (VECO) upgraded to Buy from Hold at Noble Financial... Wolverine World Wide (WWW) upgraded to Neutral from Underperform at Sterne Agee.
08:41 EDTHSPThe Medicines Co. says not giving financial guidance due to Hospira suit
Subscribe for More Information
06:01 EDTDANOYDanone upgraded to Neutral from Underperform at Exane BNP Paribas
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use